Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$19.60 USD
-0.06 (-0.31%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $19.61 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
FMS 19.60 -0.06(-0.31%)
Will FMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FMS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FMS
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
FMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
Can These 3 Medical Device Stocks Hit Earnings This Season?
Other News for FMS
Warning: FMS is at high risk of cutting its dividend
Current Analysis: Fresenius Medical Care (FMS)
Jefferies Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)
Fresenius Medical Care AG & Co. KGaA (0H9X) Gets a Sell from J.P. Morgan
GLOBAL BROKER RATINGS: Citi says 'buy' Glencore; Deutsche cuts Evotec